Affordable Access

deepdyve-link
Publisher Website

Naked-eye nanobiosensor for therapeutic drug monitoring of methotrexate.

Authors
  • Yockell-Lelièvre, H1
  • Bukar, N1
  • Toulouse, J L1
  • Pelletier, J N2
  • Masson, J-F3
  • 1 Département de chimie, Université de Montréal, CP 6128 Succ. Centre-Ville, Montreal, QC, CanadaH3C 3J7. [email protected] , (Canada)
  • 2 Département de chimie, Université de Montréal, CP 6128 Succ. Centre-Ville, Montreal, QC, CanadaH3C 3J7. [email protected] and PROTEO. , (Canada)
  • 3 Département de chimie, Université de Montréal, CP 6128 Succ. Centre-Ville, Montreal, QC, CanadaH3C 3J7. [email protected] and Centre for self-assembled chemical structures (CSACS). , (Canada)
Type
Published Article
Journal
The Analyst
Publisher
The Royal Society of Chemistry
Publication Date
Jan 21, 2016
Volume
141
Issue
2
Pages
697–703
Identifiers
DOI: 10.1039/c5an00996k
PMID: 26229988
Source
Medline
License
Unknown

Abstract

Sensing of methotrexate at clinically-relevant concentrations was achieved with a plasmon-coupling assay. In this assay, free methotrexate and folic acid Au nanoparticles competed for human dihydrofolate reductase (hDHFR)-functionalized Au nanoparticles (Au NP). The hDHFR-functionalized Au NPs were immobilized on a small glass sensor inserted in a portable 4-channel LSPR reader. This allowed rapid (minutes) and sensitive (nanomolar range) measurement of methotrexate concentration by means of total internal reflection plasmonic spectroscopy. The large bathochromic shifts of the plasmon-coupling assay led to striking colour changes visible to the naked eye for methotrexate at clinically-relevant concentrations. The results demonstrate the potential for therapeutic drug monitoring of a widely used chemotherapy agent, as assessed with the naked eye.

Report this publication

Statistics

Seen <100 times